New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 24, 2013
07:14 EDTSPNCFinal results of Spectranetics study supports successful laser atherectomy use
Spectranetics announced final results from the Photo-Ablation using the Turbo-Booster and Excimer Laser for In-Stent Restenosis Treatment, or PATENT, study evaluating the safety and efficacy of the Spectranetics peripheral laser atherectomy catheters for the treatment of in-stent restenosis, or ISR, in the femoropopliteal artery in the leg. ISR occurs as a result of narrowing of the artery in patients who have undergone stenting for the treatment of peripheral arterial disease, or PAD. There is currently no FDA-cleared or approved device to treat peripheral in-stent restenosis, which remains a major unsolved medical problem. Ninety patients participated in this prospective, multi-center registry, which completed enrollment in December 2011 at five centers in Germany. The study evaluated extremely complex patients who had a previously failed stent procedure to address peripheral arterial disease. Final results presented indicate 82% and 52% freedom from target lesion revascularization, or TLR, at six and 12 months, respectively. Laser atherectomy demonstrated excellent midterm primary patency of 64% as compared to 37% with balloon angioplasty primary patency as published in previous clinical registries. This is a significant improvement considering the challenging nature of these patients.
News For SPNC From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
July 24, 2015
09:31 EDTSPNCSpectranetics selloff on Q2 results warranted, says Northland
Northland views the post-earnings pullback in shares of Spectranetics as warranted and remains negative on the company's fundamentals. The lowered FY15 revenue "set off alarm bells" and the company's explanations for growth rates "provided a confusing picture," the firm tells investors in a research note.
08:57 EDTSPNCSpectranetics guidance is balance of downside/upside scenarios, says Canaccord
Canaccord believes Spectranetics' disappointing guidance will lead to a lower valuation for shares, but the firm sees it as a better balance of downside/upside scenarios. The firm said the company's best chance for redemption is better execution and does not believe its core business in VI and LM has vanished. Canaccord maintained its Buy rating but lowered its price target to $26.50 from $36 on Spectranetics shares.
06:59 EDTSPNCSpectranetics removed from Analyst Focus List at JPMorgan
Subscribe for More Information
July 23, 2015
16:08 EDTSPNCSpectranetics sees FY15 EPS (96c)-($1.07), consensus ($1.05)
Subscribe for More Information
16:06 EDTSPNCSpectranetics lowers FY15 revenue view to $240M-$250M from $258M
Subscribe for More Information
16:05 EDTSPNCSpectranetics reports Q2 EPS (22c), consensus (31c)
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use